Jenex receives TherOZap results for Zika testing
The Jenex Corp. has received initial results on Zika virus testing with TherOZap. Results have shown that infected cells treated with TherOZap had “lower cytopathic effect” compared with infected cells that did not receive treatment.
THE JENEX Corp. has received promising initial results on the Zika virus testing with TherOZap.
D r . Alyson Kelvin at UHN (University Health Network) reported the following: “To evaluate the effectiveness of the Jenex TherOZap device against the infectivity of Zika virus, cells were infected with a range of Zika virus doses and treated with the Jenex device with heat. In the cells that received the lowest viral dose, initial results showed infected cells that had been treated with the Jenex TherOZap device had a markedly lower cytopathic effect compared to infected cells that did not receive treatment. These preliminary results need to be confirmed through repeated testing as well as by measurement of virus viability. Cytopathic effect is a mea sure of cel lu lar pathogenesis and cellular viability in relation to viral infection; results of a viral replication assay and measurements of live viral activity are pending.”
Rob Fia, chief executive officer of Jenex, commented: “We are pleased with the initial test results on the Zika virus with our patent-pending TherOZap technology. Jenex is excited about these initial tests results, and we look forward to further data as it becomes available from Techna Institute at UHN. Jenex will have more to report to over the next several weeks.”
About The Jenex Corp.
Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. The company’s breakthrough proprietary technology delivers effective, non-invasive and pain-free skin care.
Jenex received a Class II medical device status from the U.S. Food and Drug Administration for its platform technology that is indicated for the relief of the pain, itch and inflammation from over 20,000 different insect stings and bites (including bees, wasps, hornets, mosquitoes, black flies and jellyfish).
We seek Safe Harbor.
Roberto Fia, John R Gamble, Joseph Ching-Hiang Heng
(JEN) Shares: 135,043,740